The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

NAN-190     2-[4-[4-(2- methoxyphenyl)piperazin-1...

Synonyms: CHEMBL1256701, SureCN4083153, CHEBI:64123, N3529_SIGMA, ANW-62583, ...
This record was replaced with 4431.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lopac-N-3529


Psychiatry related information on Lopac-N-3529

  • Conversely, ICV injections of the 5-HT(1A) receptor antagonist NAN-190 attenuated the effect of CRH on locomotor activity when given in combination with CRH but had no effect when administered alone [6].
  • When administered alone, NAN-190 suppressed REM sleep in the first 2 h, and reduced SWS-2 in the first 4 after administration [7].
  • The (5-HT)IA antagonist NAN-190 prevented the stimulus generalization from indorenate to 8-OH-DPAT [8].
  • NAN-190 also suppressed selectively NREM sleep slow-wave activity in both fronto-frontal (FF) and FP EEG power spectrum [7].
  • NAN-190 was not effective at 0.125 or 1.25 microg any dose but reversed amnesia when given at 1.250 microg simultaneously with both effective doses of 8-OH-DPAT [9].

High impact information on Lopac-N-3529

  • This effect is antagonized by the putative 5-HT1A-selective antagonist NAN 190 [10].
  • Only NAN-190 (a 5-HT1A antagonist) inhibited the effect of 5-HT, suggesting involvement of this receptor [11].
  • This effect was blocked in the substantia nigra by the 5-HT1B/1D receptor antagonist GR-127,935 and in the former two regions by the 5-HT1A antagonist NAN-190 [12].
  • In addition, NAN-190, ketanserin, and MDL-72222 were administered to selectively block 5-HT1A, 5-HT2A, and 5-HT3 receptors, respectively [13].
  • At a concentration of 10(-4) M at 72 hours the 5HT1A antagonist NAN-190 hydrobromide and the 5-hydroxytryptamine1B antagonist SB224289 HCl (Tocris Laboratories, Bristol, United Kingdom) induced a 20% and 78% inhibitory effect, respectively, on PC3 cell growth compared to that in controls (p < 0.0001) [14].

Chemical compound and disease context of Lopac-N-3529

  • The 5-HT1A antagonist, NAN-190 (2 mg/kg, s.c.), blocked both hypothermic and analgesic effects, while systemic administration of the opioid antagonist, naloxone (1 mg/kg, s.c.), did not change the pattern of buspirone-induced hypothermia or analgesia [15].
  • However, NAN-190 (1-8 mg/kg) given alone, produced hypothermia and increased the concentration of corticosterone in serum [16].
  • WAY 100635 (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl] ethyl]-N-(2-pyridinyl) cyclohexanecarboxamide), a highly selective 5-HT(1A) receptor antagonist, increased NAN-190-induced hypotension (p<0.05) [3].
  • In contrast, smaller doses of NAN-190 had a significant effect, whereas higher doses (2.5-10.0 mg/kg) decreased locomotor activity and other active behaviours, a profile similar to that produced by the alpha1-adrenoceptor antagonist prazosin (2.5 mg/kg), which also inhibited open arm activity [17].
  • Methamphetamine (1.5 mg/kg, i.p) produced a significant increase in locomotor activity, which was significantly antagonized by NAN-190 at a dose of 4 mg/kg, i.p. NAN-190 did not alter the antinociceptive activity of mice when it was administered alone [18].

Biological context of Lopac-N-3529

  • The i.v. injection of NAN-190 (1-300 micro/kg) dose-dependently decreased blood pressure (p<0.001), while heart rate was not significantly modified compared to saline-treated, anaesthetized adult rats [3].
  • Both compounds caused a dose-related increase in the intensity of the '5-HT syndrome'. After pretreatment with NAN 190 (100 micrograms/kg s.c.) the increases in heart rate, respiratory rate and symptoms of the '5-HT syndrome' were significantly reduced but the decreases in systolic and diastolic pressure were additive [19].
  • In this respect NAN-190 was a 250-fold more potent antagonist than prazosin (IC50 = 49 nM) [20].
  • The increased defecation induced by 8-OH-DPAT could be antagonised by pindolol and NAN-190 [21].
  • Rat pups were treated with parachloroamphetamine (PCA), 5,7-DHT or the 5-HT1a receptor antagonist NAN-190 [22].

Anatomical context of Lopac-N-3529

  • Eight of the 14 antagonists tested were effective against 5-HT(apAC) in CNS membranes with the following rank order of potency: methiothepin > metergoline approximately fluphenazine > clozapine > cyproheptadine approximately risperidone approximately ritanserin > NAN-190 [23].
  • The 5-HT1A mixed agonist-antagonist (1-(2-methoxyphenyl) 4-[4-(2-pthalimido)butyl]piperazine, i.p. NAN-190) attenuated the discriminative stimulus effects of 8-OH-DPAT injected i.p. (0.1 mg/kg), into the DRN (10 micrograms) or into the hippocampus (2 x 10 micrograms).(ABSTRACT TRUNCATED AT 250 WORDS)[24]
  • Although bilateral injections of 8-OH-DPAT (5.6 nmol/0.4 microl) or NAN-190 (5.6 nmol and 10 nmol/0.4 microl) into the amygdala did not alter OAIA, increased anxiety was observed in the EPM [25].
  • Dose-dependent attenuation was also obtained with ketaserin (0. 01-10 mg/kg), cyproheptadine (0.01-10 mg/kg), pindolol (0.1-100 mg/kg) and NAN-190 (0.1-100 mg/kg), but not with 0.01 to 10 mg/kg of ICS205-930 or M-840, and the activities were significantly correlated with the binding affinities for serotonin2 receptor on the rat cerebral cortex [26].
  • The growth-inhibition effect of a 5-HT1A antagonist (NAN-190) on PC cell lines was studied using a bromodeoxyuridine (BrdU) assay [27].

Associations of Lopac-N-3529 with other chemical compounds

  • The effect of 5-HT was blocked by the 5-HT1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide (NAN-190) but not by ketanserin, a 5-HT2A/2C antagonist [28].
  • An antagonist of 5-HT1A receptor, NAN-190, eliminates the effect of serotonin and buspirone on AA and NO/cGMP liberation [29].
  • Further, STFs evoked by LY 165,163 in the presence of apomorphine were abolished by the 5-HT1A antagonists (-)-alprenolol, BMY 7378 and NAN-190 [30].
  • DAU 6215 did not antagonize the 5-HT1A-induced membrane hyperpolarization and conductance increase, a response that was blocked by the selective 5-HT1A antagonist NAN-190 (1-(2-methoxyphenyl)-4-[4-(2-phtalamido)butyl- piperazine) [31].
  • In comparison, SDZ 216-525 is reported to have slightly higher affinity for the 5-HT1A site than 8-OH-DPAT and NAN-190 [32].

Gene context of Lopac-N-3529

  • Systemic administration of the selective 5-HT1A antagonist NAN-190 immediately after training markedly-and dose-dependently-facilitated retention in the passive-avoidance task; enhanced retention was time-dependent and was not attributable to variations in wattages of shock received by animals [33].
  • Consistent with these results, IGF-I was significantly decreased when mandibular mesenchymal cells were grown in serum-containing medium (which contains micromolar amounts of 5-HT from fetal calf serum) and treated with 10(-8) M antagonist selective for the 5-HT(1A) or 5-HT(4) receptor subtype (NAN-190 on SDZ-205,557) [34].
  • The mechanisms responsible for the NAN-190-induced hypothermia and secretion of corticosterone are still unknown, though stimulation of 5-HT1A receptors (either effect), 5-HT2 receptors and alpha 1- and alpha 2-adrenoceptors (corticosterone response) seems to be excluded [16].
  • The effect of systemically applied 8-OH-DPAT was abolished by i.p. injection of the 5-HT1A receptor antagonist, NAN-190, administered 20 min before the 8-OH-DPAT [35].
  • New arylpiperazines related to buspirone, gepirone and NAN-190 were designed and screened in silico for their 5-HT(1A) affinity and potential sites of metabolism by human cytochrome p450 (CYP3A4) [36].

Analytical, diagnostic and therapeutic context of Lopac-N-3529

  • Microinjections of NAN-190, a 5-HT-1A receptor blocker, enhanced hypoxic augmentation resulting in apneustic prolongation of inspiratory bursts [37].
  • Intrathecal injection of the 5-HT(1A) receptor antagonist NAN-190 (0.2 mM) alone did not influence Adelta- and C-responses and post-discharge of WDR neurons in normal rats [38].
  • Following perfusion of 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine (NAN-190; 10 microM), which is a selective 5-HT1A antagonist, the effect of 8-OH-DPAT was totally abolished, whereas CGS-12066B decreased extracellular ACh levels [39].
  • However, NAN-190 also increased NMDA-induced behaviour in the control group, suggesting that a tonic inhibition of this behaviour, mediated by the 5-HT1A receptor, may exist [40].
  • However, the EEG power spectral density and REM sleep suppressive effects of NAN-190 were both augmented [7].


  1. Ultrasonic vocalizations in rat pups: effects of serotonergic ligands. Olivier, B., Molewijk, H.E., van der Heyden, J.A., van Oorschot, R., Ronken, E., Mos, J., Miczek, K.A. Neuroscience and biobehavioral reviews. (1998) [Pubmed]
  2. Intracerebral actions of the 5-HT1A agonists, 8-OH-DPAT and buspirone and of the 5-HT1A partial agonist/antagonist, NAN-190, on female sexual behavior. Uphouse, L., Caldarola-Pastuszka, M., Montanez, S. Neuropharmacology (1992) [Pubmed]
  3. Evidence that NAN-190-induced hypotension involves vascular alpha1-adrenoceptor antagonism in the rat. Villalobos-Molina, R., Gallardo-Ortíz, I.A., López-Guerrero, J.J., Ibarra, M. Eur. J. Pharmacol. (2002) [Pubmed]
  4. Is NAN-190 an effective antagonist of the hypothermia and hyperglycemia induced by the 5-HT1A receptor agonist, 8-OH-DPAT? Wozniak, K.M., Durcan, M.J., Linnoila, M. Eur. J. Pharmacol. (1991) [Pubmed]
  5. Evidence for a spinal serotonergic control of the peripheral inflammation in the rat. Daher, J.B., de Melo, M.D., Tonussi, C.R. Life Sci. (2005) [Pubmed]
  6. Evidence that acute serotonergic activation potentiates the locomotor-stimulating effects of corticotropin-releasing hormone in juvenile chinook salmon (Oncorhynchus tshawytscha)( small star, filled ). Clements, S., Moore, F.L., Schreck, C.B. Hormones and behavior. (2003) [Pubmed]
  7. Sleep and EEG power spectrum effects of the 5-HT1A antagonist NAN-190 alone and in combination with citalopram. Neckelmann, D., Bjørkum, A.A., Bjorvatn, B., Ursin, R. Behav. Brain Res. (1996) [Pubmed]
  8. Discriminative stimulus properties of indorenate, a serotonin agonist. Velázquez-Martínez, D.N., López Cabrera, M., Sánchez, H., Ramírez, J.I., Hong, E. Journal of psychiatry & neuroscience : JPN. (1999) [Pubmed]
  9. Involvement of the serotonergic type 1A (5-HT1A) receptor in the agranular insular cortex in the consolidation of memory for inhibitory avoidance in rats. Mello e Souza, T., Rodrigues, C., Souza, M.M., Vinadé, E., Coitinho, A., Choi, H., Izquierdo, I. Behavioural pharmacology. (2001) [Pubmed]
  10. Serotonin receptor activation reduces calcium current in an acutely dissociated adult central neuron. Penington, N.J., Kelly, J.S. Neuron (1990) [Pubmed]
  11. Serotonin regulates mouse cranial neural crest migration. Moiseiwitsch, J.R., Lauder, J.M. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  12. 5-Hydroxytryptamine1A and 5-hydroxytryptamine1B receptors stimulate [35S]guanosine-5'-O-(3-thio)triphosphate binding to rodent brain sections as visualized by in vitro autoradiography. Waeber, C., Moskowitz, M.A. Mol. Pharmacol. (1997) [Pubmed]
  13. Joint manipulation reduces hyperalgesia by activation of monoamine receptors but not opioid or GABA receptors in the spinal cord. Skyba, D.A., Radhakrishnan, R., Rohlwing, J.J., Wright, A., Sluka, K.A. Pain (2003) [Pubmed]
  14. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation. Siddiqui, E.J., Shabbir, M., Mikhailidis, D.P., Thompson, C.S., Mumtaz, F.H. J. Urol. (2006) [Pubmed]
  15. Putative mechanisms of buspirone-induced antinociception in the rat. Giordano, J., Rogers, L. Pain (1992) [Pubmed]
  16. The behavioural, but not the hypothermic or corticosterone, response to 8-hydroxy-2-(DI-n-propylamino)-tetralin, is antagonized by NAN-190 in the rat. Przegaliński, E., Ismaiel, A.M., Chojnacka-Wójcik, E., Budziszewska, B., Tatarczyńska, E., Błaszczyńska, E. Neuropharmacology (1990) [Pubmed]
  17. Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Cao, B.J., Rodgers, R.J. Pharmacol. Biochem. Behav. (1997) [Pubmed]
  18. NAN-190, a possible specific antagonist for methamphetamine. Ginawi, O.T., Al-Majed, A.A., Al-Suwailem, A.K. Regulatory toxicology and pharmacology : RTP. (2005) [Pubmed]
  19. Are the cardiovascular effects and '5-HT syndrome' induced by MDL 73,975 and flesinoxan in the dog mediated by 5-HT1A receptors? Di Francesco, G.F. Eur. J. Pharmacol. (1994) [Pubmed]
  20. Effect of the putative 5-HT1A receptor antagonist NAN-190 on rat brain serotonergic transmission. Claustre, Y., Rouquier, L., Serrano, A., Bénavidès, J., Scatton, B. Eur. J. Pharmacol. (1991) [Pubmed]
  21. Antagonism of 8-OH-DPAT-induced behaviour in rats. Berendsen, H.H., Broekkamp, C.L., Van Delft, A.M. Eur. J. Pharmacol. (1990) [Pubmed]
  22. Synaptogenesis in the postnatal rat fascia dentata is influenced by 5-HT1a receptor activation. Faber, K.M., Haring, J.H. Brain Res. Dev. Brain Res. (1999) [Pubmed]
  23. Pharmacological characterization of an adenylyl cyclase-coupled 5-HT receptor in aplysia: comparison with mammalian 5-HT receptors. Cohen, J.E., Onyike, C.U., McElroy, V.L., Lin, A.H., Abrams, T.W. J. Neurophysiol. (2003) [Pubmed]
  24. Studies on the neuronal circuits involved in the discriminative stimulus effects of 5-hydroxytryptamine1A receptor agonists in the rat. Schreiber, R., de Vry, J. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  25. Anxiety-induced antinociception in mice: effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Nunes-de-Souza, R.L., Canto-de-Souza, A., da-Costa, M., Fornari, R.V., Graeff, F.G., Pelá, I.R. Psychopharmacology (Berl.) (2000) [Pubmed]
  26. Possible involvement of 5-HT2 receptor activation in aggravation of diet-induced acute pancreatitis in mice. Yoshino, T., Yamaguchi, I. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  27. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Dizeyi, N., Bjartell, A., Nilsson, E., Hansson, J., Gadaleanu, V., Cross, N., Abrahamsson, P.A. Prostate (2004) [Pubmed]
  28. Inhibition of N- and P-type calcium currents and the after-hyperpolarization in rat motoneurones by serotonin. Bayliss, D.A., Umemiya, M., Berger, A.J. J. Physiol. (Lond.) (1995) [Pubmed]
  29. Activation of serotonergic 5-HT1A receptor reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus. Strosznajder, J., Chalimoniuk, M., Samochocki, M. Neurochem. Int. (1996) [Pubmed]
  30. Antagonist properties of LY 165,163 at pre- and postsynaptic dopamine D2, D3 and D1 receptors: modulation of agonist actions at 5-HT1A receptors in vivo. Millan, M.J., Rivet, J.M., Audinot, V., Gobert, A., Lejeune, F., Brocco, M., Newman-Tancredi, A., Maurel-Remy, S., Bervoets, K. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  31. Effects of DAU 6215, a novel 5-hydroxytryptamine3 (5-HT3) antagonist on electrophysiological properties of the rat hippocampus. Passani, M.B., Pugliese, A.M., Azzurrini, M., Corradetti, R. Br. J. Pharmacol. (1994) [Pubmed]
  32. The novel 5-HT1A receptor antagonist, SDZ 216-525, decreases 5-HT release in rat hippocampus in vivo. Sharp, T., McQuade, R., Fozard, J.R., Hoyer, D. Br. J. Pharmacol. (1993) [Pubmed]
  33. Enhanced retention in the passive-avoidance task by 5-HT(1A) receptor blockade is not associated with increased activity of the central nucleus of the amygdala. Schneider, A.M., Wilkins, E., Firestone, A., Everbach, E.C., Naylor, J.C., Simson, P.E. Learn. Mem. (2003) [Pubmed]
  34. Serotonin receptor agonists that increase cyclic AMP positively regulate IGF-I in mouse mandibular mesenchymal cells. Lambert, H.W., Lauder, J.M. Dev. Neurosci. (1999) [Pubmed]
  35. Serotonergic inhibition of extracellular glutamate in the suprachiasmatic nuclear region assessed using in vivo brain microdialysis. Srkalovic, G., Selim, M., Rea, M.A., Glass, J.D. Brain Res. (1994) [Pubmed]
  36. The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Tandon, M., O'Donnell, M.M., Porte, A., Vensel, D., Yang, D., Palma, R., Beresford, A., Ashwell, M.A. Bioorg. Med. Chem. Lett. (2004) [Pubmed]
  37. Neurotransmitters and neuromodulators controlling the hypoxic respiratory response in anaesthetized cats. Richter, D.W., Schmidt-Garcon, P., Pierrefiche, O., Bischoff, A.M., Lalley, P.M. J. Physiol. (Lond.) (1999) [Pubmed]
  38. The role of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptors in modulating spinal nociceptive transmission in normal and carrageenan-injected rats. Zhang, Y., Yang, Z., Gao, X., Wu, G. Pain (2001) [Pubmed]
  39. Hippocampal serotonin 5-HT1A receptor enhances acetylcholine release in conscious rats. Izumi, J., Washizuka, M., Miura, N., Hiraga, Y., Ikeda, Y. J. Neurochem. (1994) [Pubmed]
  40. Reduction of NMDA-induced behaviour after acute and chronic administration of desipramine in mice. Mjellem, N., Lund, A., Hole, K. Neuropharmacology (1993) [Pubmed]
WikiGenes - Universities